This clinical trial is focused on studying treatments for children with certain types of brain tumors, specifically medulloblastoma, ependymoma, and atypical teratoid rhabdoid tumor (ATRT). These are serious conditions where abnormal cells form in the tissues of the brain. The study aims to explore the effectiveness of a combination of medications that target the blood vessels that supply the tumor, a process known as anti-angiogenesis therapy. The medications being tested include Cytarabine, Celecoxib, Cyclophosphamide, Etoposide, Bevacizumab, Fenofibrate, and Thalidomide. Some of these medications are given as injections, while others are taken orally as capsules.
The purpose of the study is to determine how well these treatments work in stopping the growth of these tumors. Participants in the study will receive these medications over a period of time, and their health will be monitored closely by the research team. The study will look at how the tumors respond to the treatment, whether they shrink, stay the same, or grow, and how long the patients remain free of tumor growth. The study will also monitor the overall health and quality of life of the participants during and after the treatment.
Throughout the study, participants will receive regular check-ups and tests to track their progress. The research team will evaluate the safety and side effects of the treatments, ensuring that any adverse effects are managed promptly. The study is designed to gather important information that could lead to better treatment options for children with these challenging brain tumors in the future.



Austria
Czechia
Denmark
France
Norway
Spain
Sweden